Solid lipid non-particles (SLN);Kati lipit nanopartiküller (SLN)

Fabad Journal of Pharmaceutical Sciences

Volumn 25, Issue 4, 2000, Pages 167-179

  Demirel, M ^a   Yazan, Y ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Characterization; Preparation; Solid lipid nanoparticles; Use

Indexed keywords

AMBROXOL; AMPHOTERICIN B LIPID COMPLEX; DOUNOXOME; DOXORUBICIN; HEPATITIS A VACCINE; LIPID EMULSION; LIPOSOME; LUNG SURFACTANT EXTRACT; MICROSPHERE; MONOMER; ORGANIC SOLVENT; POLYMER; SOLID LIPID NANOPARTICLE; TOXIC SUBSTANCE; UNCLASSIFIED DRUG;

BIODEGRADATION; COLLOID; DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG RELEASE; DRUG SAFETY; FILTRATION; HYDROPHILICITY; LIPOPHILICITY; PARTICLE SIZE; RADIATION STERILIZATION; REVIEW;

EID: 0034463629     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction
2. Spray-drying of solid lipid nanoparticles (SLNTM)
3. Solid lipid nanoparticles (SLN) for controlled drug delivery, I. Production, characterization and sterilization
4. Production of solid lipid nanoparticles (SLN) for controlled drug delivery
5. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN)
6. Sterilization of drug-free and tetracaine-loaded solid lipid nanoparticles (SLN)
7. Lipozomlar
8. Particulate systems for the controlled delivery of active compounds in pharmaceutics and cosmetics
9. Solid lipid nanoparticles (SLNTM) for oral administration - Drug incorporation and degradation
10. Solid lipid nanoparticles (SLN) - An alternative colloidal carrier system for controlled drug delivery
11. Potential of solid lipid nanoparticles (SLN) for controlled drug delivery
12. Solid lipid nanoparticles- Determination of in vivo toxicity
13. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant
14. Effect of storage conditions on long-term stability of "solid lipid nanoparticles" (SLN) in aqueous dispersion
15. Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles
16. Thermo-analysis of the recrystallization process of melt-homogenized glyceride nanoparticles
17. Solid lipid nanoparticles stabilized by tyloxapol
18. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol, I. Preparation and particle size determination
19. Comparison of parenteral lipid emulsions and solid lipid nanoparticles
20. Lyophilization of solid lipid nanoparticles (SLN)
21. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles
22. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy
23. Drug incorporation and delivery of prednisolone loaded solid lipid nanoparticles
24. Cellulose micro-particles in drug delivery
25. Relationships between manufacturing parameters and pharmaceutical-technological requirements on biodegradable micro-particles
26. Drug targeting with nanoparticles
27. Characterization of solid lipid nanoparticles by atomic force microscopy
28. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time